TUSTIN, Calif., April 3, 2008 /PRNewswire-FirstCall/ -- AMDL, Inc. (Amex: ADL), headquartered in Tustin, California, with operations in Shenzhen, Jiangxi, and Jilin, China, is a vertically integrated specialty pharmaceutical company. In combination with its subsidiary Jade Pharmaceutical Inc. ("JPI"), AMDL engages in the research, development, manufacture, and marketing of diagnostic products. Today, AMDL announced that it has entered into an exclusive sublicense (subject to certain terms and conditions) agreement with MyGene International, Inc. ("MGI," USA) for the MyGene HPV Chip Kit, a diagnostic product for in-vitro genotype testing in women with the Human Papilloma Virus (HPV). The agreement between MGI and AMDL is an exclusive sublicense to use the patents, trademark, and technology in manufacturing, promoting, marketing, distributing, and selling the MyGene HPV Test Kit in the countries of China (including Hong Kong), Taiwan, Singapore, Malaysia, Thailand, Cambodia, and Vietnam. MGI owns an exclusive worldwide license (with rights to sublicense) for the MyGene HPV Test Kit (excluding Korea).
HPV is the most common sexually transmitted infection. Globally there
are approximately 330 million women presently infected with HPV, with 70%
of existing infections in Asian populations. The virus infects the skin and
mucous membranes. There are more than 30 important HPV types that can
infect the genital areas of men and women, including the skin of the penis,
vulva (area outside the vagina), and anus, and the linings of the vagina,
cervix, and rectum. Most people who become infected with certain types of
HPV do not even know they have it. Cervical cancer, in which malignant
cells form in the tissue of the cervix, is third leading canc
|SOURCE AMDL, Inc.|
Copyright©2008 PR Newswire.
All rights reserved